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Widely expressed Rukl/CIN��/SETA�� also identi-
fied as SH3KBP� and C��BP3 is an adaptor protein 
composed of three SH3 domains�� Pro- and Ser-rich 
sequences�� and C-terminal coiled-coil region. Sequence 
identity �etween rat �Ruk and SETA���� mouse �SH3KBP��� 
and human �CIN�� and C��BP3�� orthologues varies 
�etween 9� and 9�% [���]. Ruk/cin85 gene gives more 
then one protein product. Northern hy�ridization�� direct 
c�NA cloning�� analysis of EST clones and organization of 
genomic loci in the data �anks found multiple ruk/cin85 
transcripts encoding different Ruk/CIN�� isoforms [���� �]. 
Some of them reveal tissue specific or developmentally 
regulated expression patterns [��� ��� ���� �]. c�NAs encod-
ing isoforms without the first N-terminal SH3 domain 
�SETA and C��BP3���� two N-terminal SH3 domains �Rukm 
and SH3KBP����� and a shortest Ruks isoform containing 
only coiled-coil region have �een cloned until now [3���� 
�]. However results of Finnis et al. suggest that additional 
splice variants remain to �e discovered [�].
�iverse protein �inding domains of Rukl/CIN�� 
allow this protein to assem�le various multiprotein 
complexes involved in several important intracellular 
processes [��]. For example�� in complex with C�l and 
endophilin�� CIN�� regulates clathrin-mediated endo-
cytosis of activated receptor tyrosine kinases [9�� ��]. 
Role of Rukl/CIN�� in apoptosis has also �een demon-
strated. Firstly�� it was found that overexpression of Rukl 
in cultured sympathetic and sensory neurons leads to 
apoptic death�� �ut co-expression of activated forms 
of catalytic su�unit of PI 3-kinase or its downstream 
effector PKB/Akt rescue this effect [�]. It was shown 
that complex set of intra- and intermolecular interac-
tions �etween Rukl and p��α regulatory su�units of 
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PI 3-kinase results in inhi�ition of this enzyme in vitro 
[��� ��]. This makes Rukl functionally similar to PTEN�� an 
acknowledged tumor suppressor [��]. Important fea-
ture of the functional interplay �etween Ruk isoforms is 
the a�ility of Rukm �the form with only one SH3 domain�� 
to act as dominant-negative regulator of a pro-apoptic 
function of Rukl in cultured neurons [�]. It has also �een 
demonstrated that SETA protein�� which retains two SH3 
domains�� is often overexpressed in gliomas and a�le to 
sensitize astrocytes to apoptosis in response to �NA 
damage [�3]. As it was suggested�� interaction �etween 
SETA�� AIP�/Alix and ALG-� proteins might comprise 
a mechanism of pro-apoptic function of SETA in glial 
cells. CIN�� involvement in the signalling complex with 
TNFR��� which lacks a tyrosine kinase domain�� was 
descri�ed �y Narita et al. [�4]. Authors showed that 
CIN�� associates with the cytoplasmic tail of TNFR� 
indirectly through Src and modulates TNF-α-induced 
apoptosis. In addition�� CIN�� and C��BP3 have �een 
shown to regulate B- and T-cell receptor signalling�� 
rearrangement of actin cytoskeleton and cell adhesion�� 
play an important role in HSV-� infection and �iology 
of infected cells [��� �����]. Taken together�� availa�le 
functional data suggest that ruk/cin85/seta gene and 
encoded proteins play important roles in the regula-
tion of homeostasis in normal cells and are also may 
�e involved in oncogenic transformation.
Further comprehensive analysis of expression and 
function of Ruk/CIN�� proteins in �oth normal and 
tumor cells requires highly specific anti�odies. More-
over�� to study protein-protein interactions mediated �y 
native Ruk/CIN�� proteins�� anti�odies�� which work well 
and relia�ly not only in Western �lotting �ut also in im-
munoprecipitation and immunohistochemistry as well 
as in immunofluorescence analysis�� are required. Here 
we report development of N-terminal monoclonal and 
C-terminal polyclonal anti�odies against Ruk/CIN�� 
and analysis of Ruk/CIN�� expression patterns in cell 
lines of various tissue origins�� as well as in melanoma 
samples using these anti�odies.
MATERIALS ANd METhOdS
Expression plasmids. pCMV� expression plasmids 
encoding various Ruk isoforms and mutants with C-ter-
minal FLAG-tag ��Y����K�� and pGEX-�T expression 
plasmids encoding GST-fusion SH3A�� SH3B�� SH3C 
domains and Ruks isoform were descri�ed previously 
[��]. Expression plasmid encoding GST-3SH3 CIN�� 
fragment was provided �y I. �ikic �Institute of Bioche-
mistry II�� Germany��. pc�NA 3.� plasmid encoding myc-
tagged C��AP was provided �y A. Shaw �Washington 
University School of Medicine�� USA��. An anti-FLAG-tag�� 
anti-myc-tag anti�odies and anti-β-actin anti�odies were 
from �Sigma�� USA���� polyclonal anti-C��AP were from 
�Santa Cruz Biotech�� USA���� and secondary horseradish 
peroxidase-conjugated anti-mouse or anti-ra��it IgG 
anti�odies were purchased from �Promega�� USA��. All 
reagents for cell culture were from Gi�coBRL. Samples 
of non-transformed human skin and melanoma were 
o�tained from Lviv Regional Oncological Centre.
Cell culture and transfection. Mouse fi�ro�last 
NIH3T3�� African green monkey kidney Cos ��� human 
em�ryonic kidney HEK�93�� human cervix adenocar-
cinoma HeLa S3�� Madin-�ar�y canine kidney M�CK�� 
rat glioma C���� and human lung adenocarcinoma A�49 
cells were maintained in �ul�ecco’s modified Eagle’s 
medium ��MEM�� while mouse leukemic L������ human 
Caucasian Burkitt’s lymphoma Ramos�� and human 
myelomonocytic leukemia U93� cells were grown in 
RPMI-���4� medium supplemented with ��% FCS�� 
� mM L-glutamine�� �� IU/ml penicillin�� and �� μg/ml 
streptomycin in humidified atmosphere containing 
�% CO� at 3� °C. In transient transfection procedure�� 
HEK�93 cells were plated on �� cm diameter dishes 
and transfected with �� μg of plasmid �NA �y a modified 
calcium phosphate method [��]. Su�confluent cultures 
of cells used and HEK�93 cells�� �4 hrs after transfec-
tion�� were washed twice with cold PBS and lysed in the 
lysis �uffer �LB�� containing �� mM Tris�� pH �.��� ��� mM 
NaCI�� �% Triton X-����� � mM E�TA�� �� mM NaF�� � mM 
Na orthovanadate�� � mM PMSF�� and a cocktail of pro-
tease inhi�itors from Roche at 4 °C for �� min. Lysates 
were cleared �y centrifugation at ������� g for �� min 
at 4 °C and supernatants were used for further experi-
ments. Normal and tumor tissues were disrupted with 
liquid nitrogen an then lysed in LB.
Expression and affinity purification of ����fu�
sion fra�ments of �u��C����� protein.    GST-fusion 
constructs were expressed in IPTG-induced Esche­
richia coli BL21 at 3� °C for 4 hr. Cells were pelleted at 
3����� g for �� min at 4 °C. Pellets were washed in PBS 
and resuspended in the �uffer containing �� mM Tris�� 
pH �.��� ��� mM NaCI�� �% Triton X-����� � mg/ml lyso-
zyme�� and protease inhi�itors. After one freeze-thaw 
cycle�� �acteria were sonicated on ice and cleared from 
cell de�ris �y centrifugation at �3����� g for 3� min at 
4 °C. The efficiency of �acterial lysis was checked �y 
S�S-PAGE. The GST-fusion proteins were isolated 
from the supernatants using glutathione-Sepharose 
�eads�� as recommended �y the manufacturer �Amer-
sham Pharmacia Biotech�� UK��.
�eneration of polyclonal and monoclonal an�
tibodies to �u��C����� protein. Polyclonal anti-Ruk 
anti�odies were produced in ra��it against recom�inant 
GST-fused the shortest Ruk isoform�� Ruks�� which con-
tains common for all isoforms C-terminal coiled-coil 
region. The anti-Ruks anti�odies were affinity purified 
from immune serum stepwise on E. coli proteins-4B-
Sepharose�� GST-4B-Sepharose�� and�� finally�� on Ruks-
4B-Sepharose. All proteins used in purification proce-
dure were covalently conjugated to CNBr 4B-Separose 
as recommended �y the manufacturer �Sigma-Aldrich��. 
Monoclonal anti�odies against GST-fusion protein��  
which includes three SH3 domains of CIN���� were  
generated essentially as descri�ed [�9]. Specific IgGs 
were purifed from hy�ridoma medium of exponentially 
growing clones or ascitic fluid produced in mice [��].
Western blottin� and immunoprecipitation. 
Cell lysates and tissue extracts were �oiled for � min 
with � x Laemmli’s sample �uffer and electrophoresed 
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on gradient �����%�� S�S-polyacrylamide gel [��]. 
Then proteins were electrophoretically transferred 
to Immo�ilon-P mem�rane �Millipore Corp.�� USA�� in 
�uffer containing �� mM Tris�� �9�.� mM Glycine�� ��% 
methanol at ��� mA for � hrs [��]. After �locking with 
PBST �PBS/�.��% Tween-���� containing �% dried skim 
milk�� the mem�rane was incu�ated with the appropriate 
primary anti�ody followed �y incu�ation with secondary 
anti-mouse or anti-ra��it IgGs conjugated with horse-
radish peroxidase. The filter was washed three times 
with PBST and two times with PBS and su�jected to 
ECL detection system �Amersham Biosciences�� USA��. 
For Ruk/CIN�� immunoprecipitation�� precleared cell 
lysates ��.� mg of total protein�� were mixed with �� μl of 
anti-SH3A mAB-immo�ilized �eads followed �y incu�a-
tion for 3 h at 4 °C and constant mixing. Anti-SH3A mA� 
was coupled to protein G-Sepharose �eads �Amersham 
Biosciences�� USA�� using dimethylpimelimidate �Sigma�� 
according to manufactures’ protocol. Myc-tagged 
C��AP from transiently transfected HEK�93 cells was 
immunoprecipitated using monoclonal anti-myc anti-
�odies followed �y incu�ation with protein G-Sepha-
rose �eads. Thereafter�� �eads were washed ���� times 
with PBST and �oiled in S�S-loading �uffer. O�tained 
samples were analyzed �y S�S-PAGE and Western 
�lotting as descri�ed a�ove.
�mmunofluorescence microscopy. For immuno-
fluorescence analyses cells were stained with polyclonal 
anti-Ruks or monoclonal anti-SH3A anti�odies. In �rief�� 
cells were fixed with cold methanol for � min at ��� °C. 
Fixed cells on coverslips were �locked for 3� min with 
�% BSA in PBS�� incu�ated with primary anti�odies 
for �h�� and then with secondary FITC-conjugated an-
ti�odies for �h at room temperature. Afterwards cells 
were stained with 3�� nM �API solution for � min and 
mounted on glass slides with Vectashield mounting me-
dium �Vector La�oratories�� USA��. In case of polyclonal 
anti-Ruks�� perincu�ation of anti�ody with ��-fold molar 
excess of Ruks was used to confirm immunofluores-
cence specificity �see supplementary data��. Imaging 
was performed under Nikon �iaphot microscope �Nikon 
Instruments Inc.�� USA�� with Retiga �3�� CC� camera 
�QImaging Inc.�� USA�� under ��� x o�jective lens.
RESuLTS ANd dISCuSSION
The lack of knowledge regarding the �iological sig-
nificance �oth expression levels and ratios of different 
Ruk/CIN�� isoforms complicates investigation of their 
roles in cancer cells. The availa�ility of highly specific 
anti�odies recognizing different epitopes of adaptor 
protein is a prerequisite to perform a detailed analysis 
of the expression patterns of Ruk/CIN�� isoforms at 
protein level.
N-terminal half of Ruk/CIN�� molecule including 
three SH3 domains�� and its C-terminal coiled-coil re-
gion were used as antigens to produce monoclonal and 
polyclonal anti�odies�� respectively. GST-fusion forms of 
these recom�inant proteins were expressed in �acterial 
system. Using one-step affinity purification procedure 
on glutathione-Sepharose�� we o�tained milligram quan-
tities of highly pure �approx. 9�% purity�� preparations of 
GST-3SH3 and GST-Ruks �see supplementary data��.   
Immuno�lot analysis revealed that affinity purified 
polyclonal anti-Ruks anti�odies recognize equally ef-
fectively the main Flag-tagged Ruk isoforms in lysates 
of transiently transfected HEK�93 cells �Fig. ��� b��. 
Besides the endogenous full-length p�� Rukl/CIN�� 
form�� a set of proteins with lower molecular weight 
was detected as well �Fig. ��� a��. For more careful ex-
amination of the specificity of polyclonal anti�odies�� 
we performed an antigen competition experiment. For 
this purpose�� anti-Ruks anti�odies were preincu�ated 
with purified His-tagged Rukm�� and then this mixture 
was used for Western �lotting of Flag-tagged Ruk iso-
forms. We found that detection of all immunoreactive 
�ands was a�rogated �y antigen competition �data not 
shown��. In the second type of study�� we first immuno-
precipitated L���� cell lysate with anti-Ruks anti�odies 
and then Western �lotted the immunoprecipitate with 
the same anti�odies. As can �e seen from Fig. ��� c�� 
the main endogenous molecular forms of Rukl/CIN�� 
are detected in o�tained immunoprecipitate compar-
ing to whole L���� cell lysate. Low level of Rukl/CIN�� 
recovering in immunoprecipitate may �e explained �y 
restricted accessi�ility of coiled-coil domain for anti-
Ruks recognition in non-denatured conditions that 
is connected with the involvement of this region into 
homo- and heterotypic protein-protein interactions.
Immunization of male Bal�/c mice with GST-3SH3 
and generation of hy�ridoma cell lines were per-
formed essentially as descri�ed �y Savinska et al. 
[�9]. According to ELISA results�� �� hy�ridoma clones 
of ���3 analyzed produced anti�odies recognizing 
GST-3SH3 �ut not GST alone. One of the hy�ridoma 
clones �designated MISh-A����� producing the highest 
titer of anti-3SH3 anti�ody�� was recloned through two 
rounds of dilution cloning procedure. Epitope specifici-
ty of this mA� was further defined �y Western �lotting 
using lysates of HEK�93 cells transiently transfected 
with constructs encoding Rukl�� Ruk∆A and Rukm iso-
forms as well as the affinity purified preparations of 
GST-SH3A�� GST-SH3B and GST-SH3C domains of 
Ruk. As shown in Fig ���d�� MISh-A� anti�ody recognized 
full-length form of Ruk and SH3A domain only indicat-
ing its specificity for SH3A domain.
Taking into account high level of homology �39% iden-
tity and �4% similarity in amino acid sequence�� �etween 
Ruk/CIN�� and C��AP/CMS�� which �elongs to the same 
family of adaptor/scaffold proteins�� it was important to test 
cross-reactivity of produced monoclonal and polyclonal 
anti�odies. According to Western �lot analysis �Fig. ��� 
lane ����� endogenous Ruk/CIN�� and C��AP/CMS pos-
sess identical electrophoretic mo�ility in S�S-PAGE. For 
this reason�� we at first performed immunoprecipitation 
of endogenous Ruk/CIN�� and myc-tagged C��AP 
from lysates of HEK�93 cells�� transiently transfected with 
pc�NA-myc-C��AP�� followed �y immuno�lotting �see Fig. 
���. In immunoprecipitates o�tained with monoclonal anti-
SH3A and anti-myc anti�odies prominent specific �ands 
with apparent molecular weight of �� k�a corresponding 
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to Rukl/CIN�� �lane ��� and myc-tagged C��AP �lane 4�� 
were detected. Very faint Ruk/CIN��- and C��AP-spe-
cific �ands were revealed in anti-myc �WB with anti-Ruks 
anti�odies�� lane 4�� and anti-SH3A �WB with anti-C��AP 
anti�odies�� lane ��� immunoprecipitates correspondingly. 
O�tained data are in agreement with previous results [��] 
indicating the existence of oligomerization �etween two   
proteins in living cells. 
Thus�� produced C-terminal polyclonal and N-termi-    
nal monoclonal anti�odies possess Ruk/CIN��-spe-
cificity and may �e used further to study expression of 
Ruk/CIN�� isoforms in cell lines of different species 
and tissue origins as well as tumour samples using dif-
ferent approaches. The main immunoreactive �ands    
in total cell lysates detected with anti-Ruks anti�odies 
are presented �y proteins with apparent molecular 
weights of �3��� ������� ������� �������� 34�4� and 
�9 k�a �Fig. 3��. According to the current experimental      
data�� multiple molecular forms of Ruk/CIN���� identi-
fied �y Western-�lot analysis with C-terminal anti�od-
ies�� may result from alternative splicing of pre-mRNA 
��� k�a full-length form�� �� k�a form without first 
SH3A domain�� ��� k�a form without two SH3 domain�� 
and ��� k�a Ruks form containing C-terminal coiled-coil 
Fig. 1. Specificity of produced C-terminal anti-Ruks polyclonal anti�odies �a–c�� and N-terminal monoclonal anti-SH3A anti�ody �d��. 
a, b�� immuno�lot analysis of lysates of ����93 cells transiently transfected with constructs encoding Flag-tagged isoforms of Ruk��                
� — Rukl; � — Ruk∆A; 3 — Rukm; 4 — Ruke; � — Rukh; �� — Ruks; c�� immunoprecipitation of endogenous Ruk isoforms from lysate of 
L���� cells using anti-Ruks anti�odies�� � — immunoprecipitate; � — whole cell lysate; d�� epitope specificity of MISh-A� hy�ridoma   
clone. Immuno�lot analysis of lysates of HEK�93 cells transiently transfected with constructs encoding Flag-tagged Ruk         l �1���� Ruk∆A �2�� 
and Rukm �3�� isoforms�� and the affinity purified preparations of GST-SH3C �4���� GST-SH3B �5�� and GST-SH3A �6�� domains of Ruk
Fig. 2. Analysis of the crossreactivity of anti-Ruks polyclonal and MISh-� monoclonal anti�odies to C��AP�� total cell lysates of non-         
transfected ����93 cells �1�� and HEK�93 cells transfected with pc�NA-myc-tag C��AP �3���� proteins immunoprecipitated from 
lysates of transfected ����93 cells with monoclonal anti-SH3A �2�� and anti-myc �4�� anti�odies
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region�� [�]; post-translational modification through 
u�iquitination ��3� k�a�� [�3] and limited proteolysis 
caused �y the presence of PEST-motifs in C-terminal 
half of polypeptide chain �p4��� [��� �4]. The existence 
of multiple sites for Ser/Thr-specific protein kinases in 
Ruk/CIN�� structure allow us to suppose that su�forms 
around indicated molecular weights are mainly the 
result of post-translational modification of Ruk/CIN�� 
molecular forms through phosphorylation. The highest  
levels of full-length form of Ruk/CIN�� are o�served in 
L������ Ramos�� HeLa S3�� C�� and U93� cells while lower 
expression is revealed in NIH3T3 cells and low to unde-
tecta�le � in A�49 cells. As can �een seen in Western �lot 
p�� generally migrates as dou�let with more prominent 
upper �and for exception of Cos� and M�CK cells for 
which the lower �and is stoichiometrically greater. These 
results generally agree with Western-�lot analysis using 
monoclonal anti-SHA anti�ody �Fig. 3��. However�� in cases 
of Cos� and M�CK cells anti-SH3A anti�ody recognizes 
only upper faint �and. It is possi�le that specific features 
of p�� post-translational modification in different cell lines 
can determine differential recognition of these su�forms 
�y MISh-A� anti�ody. The o�tained data also show that 
expression of p�� is high in HEK�93�� Ramos and M�CK 
cells�� while p������ — in NIH3T3�� M�CK and C�� cells. 
P��� is detected in Cos� and L���� cells only. Thus�� the 
patterns of multiple Ruk/CIN�� molecular forms expres-
sion are characteristic for each cell line studied that may 
�e determined �y cellular context. 
Fig. 3. Patterns of Ruk/CIN�� isoforms expression in cell lines 
of various tissue origins
As it is discussed in Introduction�� the formation of 
oligomers �etween Ruk isoforms can result in different 
�iological consequences [�]. The availa�ility of specific 
Ruk/CIN�� N-terminal and C-terminal anti�odies al-
lowed precise investigation of oligomerization �etween 
different isoforms in vivo. For this purpose�� we first 
immunoprecipitated full-length form with monoclonal 
MISh-A� anti�ody�� and then performed Western �lot 
analysis using �oth polyclonal anti-Ruks anti�odies and 
MISh-A� anti�ody. We used MISh-A� anti�ody cova-
lently conjugated to protein G-Sepharose for immuno-
precipitation. The results in Fig. 4 show that anti-SH3A 
anti�ody effectively precipitates p�� from lysates of all 
cell lines studied�� HeLa S3�� HEK�93�� C�� and NIH3T3. 
Co-precipitation of proteins around molecular weight of 
������ k�a�� which might represent a form without two 
N-terminal SH3 domains�� is o�served for C�� and NIH3T3 
cells �ut not for HeLa S3 and HEK�93 cells. Please note 
specific ratios �etween these su�forms in immunopre-
cipitates in comparison to total cell lysates. Possi�ly�� 
differences in the state and composition of isoforms in 
Ruk/CIN��-mediated oligomeric complexes define their 
different �iological role in these cell lines.
Fig 4. Oligomerization �etween different Ruk/CIN�� isoforms 
in vivo. Total cell lysates of HeLa S3�� ����93�� С�� and NIH3T3 
cells were immunoprecipitated with MISh-A� anti�ody followed 
�y Western �lot analysis using anti-Ruks and MISh-A� anti�odies�� 
��� 3�� ��� � — immunoprecipitates; ��� 4�� ���� � — total cell lysates
To o�tain detailed picture of the intracellular distri�u-
tion of Ruk/CIN�� we performed further immunofluo-
rescence analysis using C���� NIH3T3 and HEK�93 cells 
as a model. In all these cells stained with polyclonal 
anti-Ruks anti�odies endogenous Ruk variants were 
localized predominantly in the cytoplasm and to a 
lesser extent in the nuclei �Fig. ���. The cytoplasmic lo-
calization revealed �oth diffuse and punctate pattern. 
Unfortunately results of immunofluorescent staining 
with monoclonal anti�ody were not reproduci�le.
Fig. 5. Immunofluorescence microscopy of C���� NIH3T3 and 
HEK�93 cells stained with polyclonal anti-Ruks anti�odies. Nuclei 
were stained with propidium iodide
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In the last series of experiments we checked conve-
nience of the produced Ruk/CIN��-specific anti�odies 
for studies of Ruk/CIN�� isoforms expression across 
a large panel of samples representing diverse human 
tissues and tumor types. For this purpose we used hu-
man non-transformed skin and melanoma samples�� 
o�tained under surgical procedures in Lviv Regional 
Oncological Center�� as a model. According to data of 
anti-RukS Western-�lot analysis�� presented at Fig. ���� 
immunoreactive �ands with apparent molecular weight 
around �� and ������ k�a are the main in extracts of 
normal skin tissue. In comparison to the adjacent nor-
mal tissue�� pattern of CIN��/Ruk molecular forms in 
melanoma samples is characterized �y the su�stantial 
increase in the expression level of full-length p�� form�� 
that presuma�ly can lead to the loss of coordinated 
control of apoptosis and proliferation in the transformed 
melanocytes [��].
Fig. 6. Patterns of Ruk/CIN�� isoforms expression in human 
non-transformed skin and melanoma samples
The o�tained results demonstrate that produced 
polyclonal and monoclonal anti�odies work well and   
relia�ly not only in Western �lotting �ut also in immu-
noprecipitation. This allows us to continue investigations       
in the field of functional proteomics including studies 
of expression and �iological role of adaptor/scaffold 
protein Ruk/CIN�� in human tumors as well as to carry 
out search for Rukl/CIN�� �inding partners. 
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ЭКСПРЕССИЯ ИЗОФОРМ АДАПТЕРНОГО БЕЛКА 
Ruk/CIN85 �� КЛЕТО�Н��� ЛИНИЯ�� РАЗЛИ�НОГО ТКАНЕ��ОГО      
ПРОИС��ОЖДЕНИЯ И МЕЛАНОМЕ �ЕЛО��ЕКА
Цель: получение моноклональных и поликлональных антител против рекомбинантных GST-кон���ированных �орм белков,   
вкл�ча�щих соответственно N-кон�еву� и �-кон�еву� части а�аптерно�о белка Ruk/CIN85. �нали�� про�иле�� �кспрессии          
и��о�орм Ruk/CIN85 и их субклеточно�� локали��а�ии в клеточных лини�х ра��лично�о тканево�о происхо��ени� и обра���ах             
меланомы человека. Методы: рекомбинантные GST-кон���ированные �ра�менты Ruk/CIN85 (GST-3SH3/CIN85 и GST-     
Ruks) �кспрессировали в бактериально�� системе с после�у�ще�� а��инно�� очистко�� на �лутатион-се�аро��е. Дл� получени� 
моноклональных антител против 3SH3 �ра�мента CIN85 исполь��овали �ибри�омну� техноло�и�. �оликлональные антитела        
против �-кон�ево�о суперспирали��ованно�о ра��она Ruk очищали и�� сыворотки иммуни��ированно�о кролика а��инно��       
хромато�ра�ие�� на Ruks-се�аро��е. �ро�или �кспрессии и��о�орм Ruk/CIN85, их оли�омери��а�и� и субклеточну� локали-     
��а�и� и��учали мето�ами Вестерн-блот анали��а, иммунопре�ипита�ии и иммуно�луорес�ентно�� микроскопии. Результаты: 
Ruk/CIN85, SH3-со�ер�ащи�� а�аптерны�� �стелла�ны���� белок, и�рает ва�ну� роль в си�нальных про�ессах клеток. N-            
кон�еву� часть молекулы CIN85, вкл�ча�щу� 3 SH3 �омена, и �-кон�ево�� суперспирали��ованны�� ра��он исполь��овали          
в качестве анти�енов �л� получени� моноклональных и поликлональных антител, соответственно. �олучены �ибри�омы, 
секретиру�щие моноклональные антитела к 3SH3-�ра�менту. �ока��ано, что о�но и�� �тих антител (MISh-A1) спе�и�ически         
у��нает �питоп, нахо��щи��с� в первом SH3� �омене а�аптерно�о белка. �оликлональные анти-Ruk     s антитела, а��инно очи-
щенные и�� сыворотки иммуни��ированно�о крол�, спе�и�ически у��навали основные и��о�ормы Ruk/CIN85, как �н�о�енные,   
так и рекомбинантные, в ли��атах клеток НЕК293. Ва�но, что полученные антитела не реа�ировали перекрестно с �D2AP, 
пре�ставителем �то�о �е семе��ства а�аптерных белков. Мно�ественные молекул�рные �ормы Ruk/CIN85 с ка�уще��с�   
молекул�рно�� массо�� 130, 80–85, 70–75, 50–56, 34–40 and 29 кДа были �етектированы в ли��атах клеток NIH3T3, Cos1,          
L1210, HEK293, Ramos, HeLa S3, MDCK, C6, A549 и U937 с помощь� анти-Ruk            s антител. Оли�омери��а�и� ме��у р85 
и р50–56 �ормами Ruk/CIN85 вы�вили в клетках C6 и NIH3T3, но не в HeLa S3 и HEK293, иммунопре�ипита�ие�� с                
помощь� антитела MISh-A1 и после�у�ще�о анти-Ruk   s Вестерн-блот анали��а. Иммуно�луорес�ентно�� микроскопие�� с 
исполь��ованием анти-Ruks антител �н�о�енные варианты Ruk вы�вл�ли преимущественно в �итопла��ме клеток �6, NIH        
3T3, HEK293 и в более ни��ко�� степени в ��ре. Высоки�� уровень �кспрессии полнора��мерно�� �ормы Ruk              l/CIN85 вы�влен  
в обра���ах меланомы человека. Выводы: про�или �кспрессии мно�ественных �н�о�енных вариантов Ruk/CIN85 и спо-  
собность к �ормировани� оли�омерных комплексов ме��у ра��личными и��о�ормами �вл��тс� характерными �л� ка��о�� 
иссле�ованно�� линии клеток. Не искл�чено, что вы�вленные особенности мо�ут опре�ел�ть спе�и�ическу� биоло�ическу� 
��начимость и��о�орм Ruk/CIN85 в ра��личных типах клеток в ��ависимости от клеточно�о контекста. �ле�ствием высоко�о            
уровн� �кспрессии полнора��мерно�� �ормы Rukl/CIN85 в обра���ах меланомы человека мо�ет быть нару�ение со�ласованно�о         
контрол� про�ессов проли�ера�ии и апопто��а в транс�ормированных мелано�итах. �нтитела, описанные в �то�� работе, 
мо�ут быть исполь��ованы �л� и��учени� �кспрессии и �унк�и�� Ruk/CIN85 в опухол�х человека.   
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�o�yright © E��erime�t�l O�cology, 2006
